Novartis investors intensify pressure on the company's M&A strategy after a string of trial failures, Michelle Carnahan ...

Novartis investors are placing increased pressure on Novartis’ dealmaking strategy after facing setbacks to drugs acquired ...

The health care industry has invested heavily in point solutions ($100 billion). We have one tool for scheduling, another for ...

The biopharmaceutical industry is undergoing a profound transformation, driven by the emergence of agentic artificial intelligence (AI). Unlike traditional AI models that require continuous human ...

A new benchmarking survey of 33 biotech and medtech leaders reveals a leadership community operating in crisis mode — and what that means for how the industry needs to rethink peer support, advisory ...

Artisan Partners' David Samra is publicly calling for Novartis to overhaul its board and compensation structure following ...

This June, ten of the life sciences industry’s most respected board members came to New York for Accenture’s second annual Life Sciences Board Forum for something this industr ...

GLP-1 medications might be most well-known as weight-loss options, but they were originally developed as a treatment for type 2 diabetes. For many patients, the drugs remain a highly effective ...

An oversubscribed $70 million Series B, co-led by Alpha Wave and YK Bioventures with Eli Lilly participation, funds clinical ...

Learn how ClaimGuardRx addresses both diversion and fraud through a single, conversational platform. Understand why the voice ...

The Trump administration adds nine drugmakers to its Most Favored Nation pricing program, GSK advances its dual-antigen mRNA ...

Governance pressure is intensifying at Novartis, with calls to penalize dealmakers for failed M&A and align executive pay ...